In another step of major industries moving into the cannabis space, generic pharmaceutical company Sandoz will now collaborate with Canadian licensed producer (LP) Tilray (NASDAQ:TLRY) for medical cannabis products.

On Tuesday (December 18), the LP confirmed a new “global framework agreement” with the life science company.


“Sandoz AG will be a valuable partner as we work together to improve access to the highest quality medical cannabis products in countries all over the world,” said Brendan Kennedy, CEO of Tilray.

Tilray already formed a relationship with the pharmaceutical world in March, when the cannabis venture announced an exclusive collaboration with Sandoz Canada, an affiliate of Sandoz International.

This is the next step between Tilray and the Canadian division of Sandoz, which itself is part of the Novartis (NYSE:NVS) group.

As part of the collaboration, the two companies could work together to commercialize non-smokable medical cannabis products. Sandoz may also participate in co-branding these products.

Through the deal, Sandoz can obtain medical cannabis products or access to Tilray’s license rights and may participate in the development of new products.

“Both companies may also partner to leverage best-in-class knowledge to educate pharmacists and physicians about medical cannabis products,” Tilray added.

Shares of Tilray shot up 16.1 percent in Tuesday’s trading session, while during after-hours trading the company was up just over 1 percent. Tilray closed at US$76.50.

The pharmaceutical industry has been at the forefront of markets predicted to be interested in partnerships in the cannabis space due to the medical aspect.

Dena Jalbert, founder and CEO of Align Business Advisory Services, previously told the Investing News Network that she expects more deals where a larger player steps into cannabis to be based on intellectual property rather than a full buyout.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES /

Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less

The following issues have been halted by IIROC:

Company: Revive Therapeutics Ltd.

Keep reading... Show less